Artivion, Inc. (AORT)

Biotechnology company focused on developing therapies for severe allergic reactions.

AORT Stock Quote

Company Report

Artivion, Inc., formerly known as CryoLife, Inc., is a global leader in manufacturing, processing, and distributing medical devices and implantable human tissues. Established in 1984 and headquartered in Kennesaw, Georgia, the company specializes in a diverse array of innovative healthcare solutions.

Artivion's product portfolio includes BioGlue, a polymer derived from bovine blood proteins used in cardiac, vascular, neurologic, and pulmonary procedures. The company also provides cardiac preservation services, PhotoFix pericardial patches, and advanced systems such as E-vita Open Plus and E-vita Open Neo for cardiovascular interventions.

Innovative engineering solutions like E-xtra and E-nside address complex aortic vascular diseases, while products such as E-vita THORACIC 3G and E-nya offer minimally invasive options for thoracic aortic aneurysms and other lesions of the descending aorta. Additionally, Artivion manufactures E-ventus BX for renal and pelvic artery treatments, E-liac for iliac artery aneurysms, and E-tegra for abdominal aortic aneurysms.

The company's comprehensive offerings extend to synthetic vascular grafts, PerClot hemostats, cardiac laser therapy products, and CryoVein and CryoArtery preservation services. Artivion also provides On-X prosthdetic heart valves, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures, and medical dissection stents to healthcare providers worldwide. Through its dedication to innovation and quality, Artivion continues to advance medical technology and enhance patient care globally.

AORT EPS Chart

AORT Revenue Chart

Stock Research

MAYS CVCO ESS WLY ALLK NVEC META

AORT Chart

View interactive chart for AORT

AORT Profile

AORT News

Analyst Ratings